{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T18:10:22Z","timestamp":1759342222975},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T00:00:00Z","timestamp":1590019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T00:00:00Z","timestamp":1590019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The anti-retroviral combination of abacavir\/lamivudine plus rilpivirine\u00a0(ABC\/3TC\/RPV) is not recommended by international guidelines as the first-line regimen. However, it is potent, well-tolerated, and affordable, especially in resource-limited settings. This study evaluates the efficacy and safety of ABC\/3TC\/RPV as an initial regimen for treatment-na\u00efve HIV-1 infected patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective study was conducted in the largest HIV care centre in Singapore, with data collected June 2011 to September 2017. All treatment-na\u00efve HIV-1 infected adults prescribed ABC\/3TC as part of their initial anti-retroviral therapy regimen were included. The third drug was a non-nucleoside reverse-transcriptase inhibitor (NNRTI) such as RPV or efavirenz (EFV), or boosted protease-inhibitor (PI). Patients were followed up for 48\u00a0weeks. The primary end-point was the percentage of patients achieving virologic suppression, analysed using on-treatment analysis. Secondary outcomes included CD4-count change, treatment discontinuation and treatment-related adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>170 patients were included in the study, 66 patients in the RPV group, 104 patients in the comparator group (EFV or boosted PI). 96% (n\u2009=\u200924) in the RPV group and 87% (n\u2009=\u200926) in the comparator group achieved viral suppression at 48\u00a0weeks (p\u2009=\u20090.28). Median (interquartile range) time to viral suppression was similar: 17 (14\u201324) weeks in the RPV group, and 21 (13\u201326) weeks in the comparator group.\u00a0There were no statistically significant differences in the CD4 count between the two groups. 14%\u00a0(n\u2009=\u20099) of patients on\u00a0RPV discontinued\u00a0treatment before 48\u00a0weeks, compared\u00a0to\u00a030% (n\u2009=\u200931) from the\u00a0comparator\u00a0group (p\u2009=\u20090.053). Of these, 23 discontinuations were due to drug adverse effects, and only 1 attributed to RPV (p\u2009&lt;\u20090.01). One patient in each group had virologic failure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>RPV is effective, safe and considerably more tolerable than compared to NNRTI or boosted PI in ABC\/3TC-containing regimens for treatment-na\u00efve patients. It offers an affordable and attractive option, especially in resource-limited settings.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12981-020-00272-5","type":"journal-article","created":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T13:02:48Z","timestamp":1590066168000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of abacavir\/lamivudine plus rilpivirine as a first-line regimen in treatment-na\u00efve HIV-1 infected adults"],"prefix":"10.1186","volume":"17","author":[{"given":"Sharlene","family":"Ho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua Guoxian","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oon Tek","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng Chuan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yee Sin","family":"Leo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David Chien Boon","family":"Lye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen Seong","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,21]]},"reference":[{"key":"272_CR1","unstructured":"World Health Organisation. Policy brief update of recommendations on first- and second-line antiretroviral regimens, 2019. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/325892\/WHO-CDS-HIV-19.15-eng.pdf. Accessed Apr 2020."},{"key":"272_CR2","unstructured":"Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Department of Health and Human Services USA; 2019. https:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adultandadolescentgl.pdf. Accessed Apr 2020."},{"key":"272_CR3","unstructured":"European AIDS Clinical Society Guidelines Version 10.0, November 2019, initial combination regimen for art-na\u00efve adult people living with HIV. https:\/\/www.eacsociety.org\/files\/2019_guidelines-10.0_final.pdf. Accessed Apr 2020."},{"issue":"3","key":"272_CR4","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/S1473-3099(17)30702-8","volume":"18","author":"RK Gupta","year":"2018","unstructured":"Gupta RK, Gregson J, Parkin N, Haile-Selassie H, Tanuri A, Andrade Forero L, et al. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. Lancet Infect Dis. 2018;18(3):346\u201355.","journal-title":"Lancet Infect Dis."},{"key":"272_CR5","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1097\/QAD.0b013e328339fe53","volume":"24","author":"A Mocroft","year":"2010","unstructured":"Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, Beniowski M, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS. 2010;24:1667\u201378.","journal-title":"AIDS"},{"key":"272_CR6","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1093\/jac\/dkv063","volume":"70","author":"E Negredo","year":"2015","unstructured":"Negredo E, Diez-P\u00e9rez A, Bonjoch A, Domingo P, P\u00e9rez-\u00c1lvarez N, Gutierrez M, et al. Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels. J Antimicrob Chemother. 2015;70:2104\u20137.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"272_CR7","first-page":"268","volume":"14","author":"A Imaz","year":"2012","unstructured":"Imaz A, Podzamczer D. The role of rilpivirine in clinical practice: strengths and weaknesses of the new nonnucleoside reverse transcriptase inhibitor for HIV therapy. AIDS Rev. 2012;14(4):268\u201378.","journal-title":"AIDS Rev."},{"issue":"1","key":"272_CR8","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1186\/s12879-018-3268-5","volume":"18","author":"L Taramasso","year":"2018","unstructured":"Taramasso L, Tatarelli P, Ricci E, Madeddu G, Menzaghi B, Squillace N, et al. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA). BMC Infect Dis. 2018;18(1):357.","journal-title":"BMC Infect Dis"},{"key":"272_CR9","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/S0140-6736(11)60936-7","volume":"378","author":"JM Molina","year":"2011","unstructured":"Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-na\u00efve adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet. 2011;378:238\u201346.","journal-title":"Lancet"},{"key":"272_CR10","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0140-6736(11)60983-5","volume":"378","author":"CJ Cohen","year":"2011","unstructured":"Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA, Ruxrungtham K, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet. 2011;378:229\u201337.","journal-title":"Lancet"},{"issue":"Suppl 3","key":"272_CR11","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.1310\/hct1403-81","volume":"14","author":"MR Nelson","year":"2013","unstructured":"Nelson MR, Elion RA, Cohen CJ, Mills A, Hodder SL, Segal-Maurer S, et al. Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine\/tenofovir DF: pooled 96-week data from ECHO and THRIVE studies. HIV Clin Trials. 2013;14(Suppl 3):S81\u201391.","journal-title":"HIV Clin Trials."},{"issue":"12","key":"272_CR12","doi-asserted-by":"publisher","first-page":"3510","DOI":"10.1093\/jac\/dkw347","volume":"71","author":"A Curran","year":"2016","unstructured":"Curran A, Rojas J, Cabello A, Troya J, Imaz A, Domingo P, et al. Effectiveness and safety of an abacavir\/lamivudine\u200a\u2009+\u2009\u200arilpivirine regimen for the treatment of HIV-1 infection in naive patients. J Antimicrob Chemother. 2016;71(12):3510\u20134.","journal-title":"J Antimicrob Chemother"},{"key":"272_CR13","unstructured":"Stanford University HIV Drug Resistance Database. https:\/\/hivdb.stanford.edu\/dr-summary\/resistance-notes\/NNRTI\/. Accessed Dec 2019."},{"issue":"4","key":"272_CR14","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1097\/QAI.0000000000000606","volume":"69","author":"N Ford","year":"2015","unstructured":"Ford N, Shubber Z, Pozniak A, Vitoria M, Doherty M, Kirby C, et al. Comparative safety and neuropsychiatric adverse events associated with efavirenz use in first-line antiretroviral therapy: a systematic review and meta-analysis of randomized trials. J Acquir Immune Defic Syndr. 2015;69(4):422\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"272_CR15","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/QAD.0000000000000911","volume":"30","author":"J van Lunzen","year":"2016","unstructured":"van Lunzen J, Antinori A, Cohen CJ, Arribas JR, Wohl DA, Rieger A, et al. Rilpivirine vs efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study. AIDS. 2016;30(2):251\u20139.","journal-title":"AIDS."},{"key":"272_CR16","unstructured":"Edurant Prescribing Information. http:\/\/www.edurant.com\/hcp\/prescribing-information. Accessed Dec 2019."},{"issue":"14","key":"272_CR17","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1097\/QAD.0000000000001120","volume":"30","author":"EF Eaton","year":"2016","unstructured":"Eaton EF, Tamhane A, Saag M, Mugavero MJ, Kilgore ML. Cost considerations in the current antiretroviral era. AIDS. 2016;30(14):2115\u20139.","journal-title":"AIDS."}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-020-00272-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-020-00272-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-020-00272-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T13:24:53Z","timestamp":1666617893000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-020-00272-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,21]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["272"],"URL":"https:\/\/doi.org\/10.1186\/s12981-020-00272-5","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,21]]},"assertion":[{"value":"22 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval for use of the clinical data was obtained from the Singapore National Healthcare Group Domain Specific Review Board (NHG DSRB reference number 2012\/00438).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}